• ACCENT Trial: Favorable safety and efficacy for narmafotinib in pancreatic cancer
• Phase 2b Study: Initiated for advanced pancreatic cancer in Q4 CY2026
• PRROSE Trial: Launched for ovarian cancer in partnership with ANZGOG
• Board Changes: Jane Bell AM appointed Chair, Dr. Warwick Tong transitions to Non-Executive Director
• Intellectual Property: New patent application extending protection to 2046

Amplia Therapeutics Ltd. has announced significant progress in its clinical development programs and leadership changes. The company presented mature data from the ACCENT trial at AACR, highlighting favorable safety and efficacy of narmafotinib in metastatic pancreatic cancer. A Phase 2b study in advanced pancreatic cancer is set to begin in Q4 CY2026, and the PRROSE trial for ovarian cancer has been launched in partnership with ANZGOG. Additionally, Jane Bell AM has been appointed Chair of the Board, and Dr. Warwick Tong has transitioned to a Non-Executive Director role. Amplia also filed a new patent application, extending its intellectual property protection through 2046. The company ended the June 2026 quarter with a cash position of A$24.0 million.

Amplia Therapeutics Ltd. anticipates critical safety data from Phase 2b study in Q2 2027.

Amplia is optimistic about the potential of narmafotinib across multiple cancer indications, with ongoing clinical trials and strategic leadership changes supporting its growth.